Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 109.8 Million USD | 370.13% |
| 2022 | -40.64 Million USD | -34.9% |
| 2021 | -30.13 Million EUR | 30.36% |
| 2020 | -43.26 Million EUR | -168.25% |
| 2019 | -16.13 Million EUR | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 28.25 Million EUR | -24.32% |
| 2016 | 37.33 Million EUR | 316.46% |
| 2015 | -17.25 Million EUR | 56.48% |
| 2014 | -39.63 Million EUR | -91.41% |
| 2013 | -20.7 Million EUR | -547.78% |
| 2012 | -3.19 Million EUR | -616.94% |
| 2011 | -445.85 Thousand EUR | 96.72% |
| 2010 | -13.59 Million EUR | -230.04% |
| 2009 | 10.45 Million EUR | -67.82% |
| 2008 | 32.49 Million EUR | 0.0% |
| 2007 | - USD | 100.0% |
| 2006 | -32.33 Million EUR | -89.57% |
| 2005 | -17.05 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 85.92 Million USD | -25.42% |
| 2024 Q3 | 34.75 Million USD | -22.7% |
| 2024 Q1 | 115.2 Million USD | 5.01% |
| 2023 Q1 | -14.38 Million USD | 64.62% |
| 2023 Q3 | 109.33 Million USD | 591.62% |
| 2023 Q2 | -22.23 Million USD | -54.64% |
| 2023 FY | 109.8 Million USD | 370.13% |
| 2023 Q4 | 109.71 Million USD | 0.35% |
| 2022 Q3 | -49.52 Million USD | -20.89% |
| 2022 Q4 | -40.64 Million USD | 17.92% |
| 2022 FY | -40.64 Million USD | -34.9% |
| 2022 Q1 | -31.88 Million USD | -4.97% |
| 2022 Q2 | -40.96 Million USD | -28.46% |
| 2021 Q2 | -18.9 Million EUR | 64.8% |
| 2021 Q3 | -19.48 Million EUR | -3.09% |
| 2021 Q4 | -30.37 Million EUR | -55.89% |
| 2021 FY | -30.13 Million EUR | 30.36% |
| 2021 Q1 | -53.7 Million EUR | -24.32% |
| 2020 Q1 | -7.24 Million EUR | 55.11% |
| 2020 FY | -43.26 Million EUR | -168.25% |
| 2020 Q4 | -43.2 Million EUR | -48.62% |
| 2020 Q3 | -29.06 Million EUR | -8.23% |
| 2020 Q2 | -26.85 Million EUR | -270.46% |
| 2019 Q4 | -16.14 Million EUR | -509.13% |
| 2019 Q1 | 6.96 Million EUR | 179.51% |
| 2019 Q2 | 1.96 Million EUR | -71.77% |
| 2019 FY | -16.13 Million EUR | 0.0% |
| 2019 Q3 | -2.65 Million EUR | -234.85% |
| 2018 Q3 | 7.87 Million EUR | -62.16% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | -8.75 Million USD | -211.18% |
| 2018 Q2 | 20.81 Million EUR | -16.15% |
| 2018 Q1 | 24.82 Million EUR | -12.15% |
| 2017 Q1 | 40.85 Million EUR | 9.42% |
| 2017 FY | 28.25 Million EUR | -24.32% |
| 2017 Q4 | 28.25 Million EUR | -51.92% |
| 2017 Q3 | 58.77 Million EUR | -21.56% |
| 2017 Q2 | 74.92 Million EUR | 83.39% |
| 2016 Q3 | -1.67 Million EUR | 72.58% |
| 2016 Q1 | -13.7 Million EUR | 20.54% |
| 2016 Q2 | -6.12 Million EUR | 55.35% |
| 2016 Q4 | 37.33 Million EUR | 2324.8% |
| 2016 FY | 37.33 Million EUR | 316.46% |
| 2015 FY | -17.25 Million EUR | 56.48% |
| 2015 Q3 | -20.83 Million EUR | 21.51% |
| 2015 Q4 | -17.25 Million EUR | 17.22% |
| 2015 Q2 | -26.54 Million EUR | 15.19% |
| 2015 Q1 | -31.3 Million EUR | 21.02% |
| 2014 FY | -39.63 Million EUR | -91.41% |
| 2014 Q4 | -39.63 Million EUR | -41.37% |
| 2014 Q3 | -28.03 Million EUR | 16.44% |
| 2014 Q2 | -33.55 Million EUR | -43.72% |
| 2014 Q1 | -23.34 Million EUR | -12.75% |
| 2013 Q2 | -5.23 Million EUR | 29.12% |
| 2013 Q4 | -20.7 Million EUR | -94.88% |
| 2013 FY | -20.7 Million EUR | -547.78% |
| 2013 Q3 | -10.62 Million EUR | -103.11% |
| 2013 Q1 | -7.38 Million EUR | -130.88% |
| 2012 Q3 | 2.05 Million EUR | 0.0% |
| 2012 Q1 | -2.29 Million EUR | -415.82% |
| 2012 Q4 | -3.19 Million EUR | -255.88% |
| 2012 FY | -3.19 Million EUR | -616.94% |
| 2011 FY | -445.85 Thousand EUR | 96.72% |
| 2011 Q3 | -11.85 Million EUR | 17.29% |
| 2011 Q1 | -20.45 Million EUR | -50.38% |
| 2011 Q2 | -14.33 Million EUR | 29.88% |
| 2011 Q4 | -445.85 Thousand EUR | 96.24% |
| 2010 Q2 | 2.45 Million EUR | -87.77% |
| 2010 FY | -13.59 Million EUR | -230.04% |
| 2010 Q1 | 20.08 Million EUR | 92.02% |
| 2010 Q4 | -13.59 Million EUR | -75.49% |
| 2010 Q3 | -7.74 Million EUR | -415.45% |
| 2009 FY | 10.45 Million EUR | -67.82% |
| 2009 Q4 | 10.45 Million EUR | 0.0% |
| 2008 FY | 32.49 Million EUR | 0.0% |
| 2007 FY | - USD | 100.0% |
| 2006 FY | -32.33 Million EUR | -89.57% |
| 2005 FY | -17.05 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 8382084.733% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -1843.994% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -156.593% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 44088.462% |
| Rebus Holdings, Inc. | 305 Thousand USD | -35901.311% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 1841.67% |
| Qrons Inc. | 351.42 Thousand USD | -31145.18% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -17543.051% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -152.807% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 538143.904% |
| Skye Bioscience, Inc. | -5.72 Million USD | 2019.184% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -596.593% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -2566.424% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -27224.692% |
| SQZ Biotechnologies Company | -36.23 Million USD | 403.008% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -4797.083% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -11742.715% |
| Mesoblast Limited | 55.85 Million USD | -96.576% |
| Marizyme, Inc. | 18.56 Million USD | -491.329% |
| Genus plc | 190.6 Million USD | 42.39% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -4811.102% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -12664.33% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -8945.645% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -16047.647% |
| ContraFect Corporation | -6.02 Million USD | 1922.171% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -81454.379% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -9403.31% |
| IMV Inc. | 7.67 Million USD | -1331.506% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -1895.748% |
| MultiCell Technologies, Inc. | 90.04 USD | -121950144.336% |
| ONE Bio Corp. | 9.04 Million USD | -1114.641% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 15060.121% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -748.169% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -7926.778% |
| Q BioMed Inc. | 4.06 Million USD | -2604.527% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -259.377% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -10796.324% |
| Biomind Labs Inc. | 711.4 Thousand USD | -15334.874% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -81.357% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -5391.87% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -757.402% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -30425.701% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -78441.387% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -552595.425% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -4886.601% |
| GB Sciences, Inc. | 1.74 Million USD | -6184.152% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 59844.923% |
| HST Global, Inc. | 96.79 Thousand USD | -113342.088% |
| CSL Limited | 10.52 Billion USD | 98.957% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -53146.823% |
| Halberd Corporation | 144.72 Thousand USD | -75772.886% |
| Enzolytics Inc. | 981.65 Thousand USD | -11085.588% |
| Agentix Corp. | 37.63 Thousand USD | -291691.342% |
| Resverlogix Corp. | 6.45 Million USD | -1602.124% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 16413.444% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 105.412% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 333.566% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1452.884% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -3953.88% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 1342.139% |
| AVAX Technologies, Inc. | -5.9 Million USD | 1960.074% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1090957.234% |
| Genscript Biotech Corporation | -1.06 Billion USD | 110.346% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -54683.667% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -4501.946% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -66646.5% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 599532.252% |
| Kadimastem Ltd | -253.1 Thousand USD | 43483.3% |
| Helix BioMedix, Inc. | -2.57 Million USD | 4372.476% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -441.547% |
| BioStem Technologies, Inc. | 4.47 Million USD | -2355.361% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -54459.909% |
| LadRx Corporation | -2.03 Million USD | 5491.882% |
| Cell Source, Inc. | 9.23 Million USD | -1089.388% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -17187.422% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -17187.422% |
| NovAccess Global Inc. | 2.17 Million USD | -4940.43% |
| Affymax, Inc. | -5.59 Million USD | 2061.837% |
| Itoco Inc. | 228.3 Thousand USD | -47995.311% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -80644.766% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -2115.13% |
| Mobile Lads Corp. | 484.23 Thousand USD | -22575.907% |
| CytoDyn Inc. | 20.26 Million USD | -441.921% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 16971351.932% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1184821.32% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -1324.915% |
| SYBLEU INC | 473.71 Thousand USD | -23079.387% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -2363.618% |
| International Stem Cell Corporation | 2.59 Million USD | -4139.537% |
| Bioxytran, Inc. | 1.89 Million USD | -5682.463% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -175831.296% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -4934.802% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -3097.554% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -1183.807% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -14112.141% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 8884.32% |
| Neutra Corp. | 52.18 Thousand USD | -210304.89% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 4511.571% |
| PureTech Health plc | -167.19 Million USD | 165.673% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 44934.795% |
| IXICO plc | -4.44 Million USD | 2570.511% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -730.653% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -100.186% |
| CSL Limited | 10.52 Billion USD | 98.957% |
| Cellectis S.A. | -43.81 Million USD | 350.586% |